Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07178444

Evaluation of the Effectiveness of an Interdisciplinary Intervention After Acute Coronary Syndrome on Low-Density Lipoprotein Cholesterol Levels

According to the World Health Organization (WHO), cardiovascular diseases are the worldwide leading cause of death. For the French public health, cardiovascular diseases are the leading cause of death for the women and the second for men. Each year in France, approximately 120,000 acute coronary syndromes (ACS) occur, including 60,000 myocardial infarctions and more than 15,000 deaths. To prevent or reverse this process, the WHO recommends early detection of the diseases and reduce behavioral and cardiovascular risk factors.

For the patient, the European Society of Cardiology (ESC) recommends the implementation of secondary prevention measures, the lifestyle modifications and the encouragement to become an actor in the management of his health. The first year, the medical follow-up is recommended at 3, 6 and 12 months.

Since 2019, in order to reduce the impact of LDL cholesterol, the ESC has recommended that LDL cholesterol levels be lower than 0.55 g/L accompanied by a reduction of at least 50% from their initial value. In 2023, it clarified this recommendation by recommending a laboratory reassessment within 4-6 weeks after hospital discharge.

The application of these recommendations comes up against the difficulties of real life:

1. The increase in the number of elderly people and people with one or more chronic diseases; 2. In France, the significant regional disparities in the number of physicians; 3. In 2022, six months after hospitalization for an ACS, only 21.6% of French patients had benefited from a cardiac rehabilitation program; 4. Within 12 months of acute coronary syndrome, only 20% to 40% of patients achieved the LDL cholesterol targets recommended by the ESC.

Given the difficulties in implementing the recommendations, investigators believe it is essential to rethink the care pathway for post-ACS patients.

The investigator's hypothesis is that, in addition to the standard pathway, a care offering access to other healthcare professionals (advanced practice nurse, dietitian, pharmacist) should increase the proportion of patients achieving LDL cholesterol targets (LDL cholesterol < 0.55 g/L and a 50% reduction in this level compared to the baseline value) at 12 months. LDL cholesterol was selected as the endpoint because it has been proven that a reduction in LDL cholesterol corresponds to a 22% reduction in cardiovascular events.

To test this hypothesis, the investigators designed a multicenter controlled and randomized trial with two parallel arms:

* "Routine Cares" arm: Each center will program cares as usual and will schedule patient follow-up according to their wishes (cardiac rehabilitation, visits to the general practitioner and/or cardiologist). * "Intervention" arm: In addition to routine care as described above, the patient will receive an interdisciplinary consultation one month after hospital discharge and three consultations with the IPA (3, 6, and 12 months).

In order for the conclusions of this protocol to reflect French practices, it is planned to include 230 people who have presented with acute coronary syndrome in four healthcare facilities in France (both in Paris and outside Paris).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier Sud Francilien, Pôle Cardiologie, Corbeil-Essonnes, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients hospitalized for ACS (ST+ or ST-), affiliated with a social security scheme, able to understand the protocol and having signed the study consent.

Exclusion criteria

  • Patients with a complication of the ACS (mechanical complication, cardiogenic shock, very severe left ventricular dysfunction, presence of an intraventricular thrombus, complex ventricular rhythm disorder) ;
  • Proven cognitive impairment or decompensated psychological/psychiatric disorder ;
  • Any progressive inflammatory and/or infectious condition ;
  • Any orthopedic problem precluding the physical activity ;
  • Current participation in any clinical research project aimed at reducing LDL cholesterol levels ;
  • Pregnant or breastfeeding woman ;
  • Patient receiving state medical assistance ;
  • Patient under guardianship or curatorship, or any other legal protection measure ;

Treatment and study plan

"New" care pathway

Behavioral

Initially, the patient will have an interdisciplinary consultation aimed at identifying personalized goals for the patient and providing educational/preventive care using tools that will be provided to all centers. This consultation will bring together a cardiologist, an advanced practice nurse (APN), a dietitian and a pharmacist. This consultation will take place approximately 4 weeks after the hospitalization for acute coronary syndrome (ACS).

Secondly, the patient will have 3 follow-up consultations with the APN (at 3, 6 and 12 months after discharge from hospitalization for an ACS). During these consultations, the APN will perform a clinical assessment, a personalized educational support, a coaching based on the patient's personalized goals, an adjustment of therapies and, depending on needs, referral to other health professionals.

Other names: Interdisciplinaire consultation, Identifying personalized goals, Educational/preventive care, Advanced practice nurse, Dietitian, Pharmacist, Acute coronary syndrome, Follow-up consultations with an advanced practice nurse, Coaching, Adjustement of therapies, Coordination of the care pathway

"Standard" care pathway

Other

The French National Health Authority recommends two medical visits (at 6 and 12 month) and, if necessary, a third one (between the first and third month post-ACS) for the monitoring of the left ventricular. - The European Society of Cardiology recommends a reassessment of the lipid profile within 4-6 weeks post-ACS.

Primary outcomes

  1. Proportion of patients reaching the LDL cholesterol target

    Time frame: At enrollment then at the 12th month

    The target is definde as LDL cholesterol level <0.55 g/L and >50% reduction from baseline

Secondary outcomes

  1. Proportion of patients reaching the LDL cholesterol target

    Time frame: At enrollment then at the first month, 6th month and 12th month

    The target for this outcome is defined as LDL cholesterol <0.55 g/L

  2. Proportion of patients reaching the LDL cholesterol target

    Time frame: At enrollment then at the first month, 6th month and 12th month

    The target for this outcome is defined as LDL cholesterol level reduction > 50% compared to baseline value

  3. Changes in cardiovascular risk factors

    Time frame: At enrollment then at the first month, 6th month and 12th month

    This outcome aims to assess changes in the patient's overall cardiovascular risk profile throughout the study. Multiple parameters will be evaluated to capture a comprehensive picture of the modifications in cardiovascular risk factors presented by each patient. The parametrers will be:

    • Dyslipidemia: Proportion of patients achieving the LDL cholesterol target set by the European Society of Cardiology (<0.55 g/L and >50% reduction from baseline)
    • Hypertension: Proportion of patients achieving a systolic blood pressure < 140 mmHg and a diastolic blood pressure < 90 mmHg
    • Percentage of patients with controlled type 2 diabetes (for a diabetic patient, HbA1c target <7%)
    • BMI
  4. Physical Activity Score

    Time frame: At enrollment then at the 6th month and 12th month

    Total score on the "Ricci and Gagnon Self-Assessment of Physical Activity" Questionnaire (activity self-assessment questionnaire).

    The minimum value is 9 The maximum value is 45 Under 18: inactive Between 18 and 35: active Over 35: very active

  5. Proportion of patients who participated in a cardiac rehabilitation program

    Time frame: At 6th month and 12th month

    This outcome aims to assess the proportion of patients who engage in a cardiac rehabilitation program following an acute coronary syndrome

  6. Proportion of patients consuming toxic substances and their quantity measured

    Time frame: At enrollment then at the 6th month and 12th month

    The substances involved are: alcohol, tobacco, and drugs

  7. Quality of life score

    Time frame: At enrollment then at the 6th month and 12th month

    Measured using the EQ-5D-5L Questionnaire (European quality of life 5 dimensions 5 levels questionnaire) The (EQ-5D-5L) questionnaire provides two types of scores. The first is an index scored derived from five health dimensions (mobility, self-care, actual activities, pain/discomfort, and anxiety/depression) converted into a single value ranged from 0 (representing health states considered worse than death) to 1(representing perfect health). The second is the EQ Visual Analogue Scale (EQ-VAS), a self-rated health measure ranging from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine") representing self-rated health.

  8. Therapeutic Compliance Score

    Time frame: At enrollment then at the 6th month and 12th month

    Measured using FREEDOM questionnaire (FREE Detection non Observance Medication) The FREEDOM questionnaire includes 11 items rated on a 4-point Likert scale ranging from "strongly disagree" to "strongly agree". The questionnaire responses will be used qualitatively, without calculation of a numerical total score, to classify patients into categories of medication adherence (low, moderate, high).

  9. List of lipid-lowering treatments taken by patients

    Time frame: At enrollment then at the first month, 6th month and 12th month

    This outcome aims to describe the lipid-lowering therapy prescribed to each patient, as well as any modifications made during follow-up. This outcome focuses solely on documenting which lipid-lowering treatments patients are receiving and does not involve any comparison or evaluation of the effectiveness or safety of different lipid-lowering therapie

  10. Number of medical (cardiologist or general practitioner) and/or paramedical (dietician, etc.) consultations

    Time frame: At 6th month and 12th month

  11. Mortality rate and the reasons

    Time frame: At 6th month and 12th month

  12. Rehospitalization rates and the reasons

    Time frame: At 6th month and 12th month

  13. Rate of cardiovascular events

    Time frame: At 12th month

  14. Estimation of cost per QALY gained and cost per serious cardiac event avoided

    Time frame: At 12th month

    QALY: quality-adjusted life year

  15. Professional satisfaction rate by using a satisfaction scale from 0 to 10

    Time frame: At 12th month

    Satisfaction with the care provided to the patient under the EDUSCA protocol

Study contacts

Contact information is provided by the study sponsor or research team.

Youcef SEKOUR

CONTACT

[email protected]

0033(0)156095823

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Ministry of Health, France

Registry information

Acronym: EDUSCA

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Sep 17, 2025
Registry last updated
Oct 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.